tiprankstipranks

Liquidia price target raised to $34 from $30 at Scotiabank

Scotiabank analyst Greg Harrison raised the firm’s price target on Liquidia (LQDA) to $34 from $30 and keeps an Outperform rating on the shares. Liquidia’s Q4 call reinforced the company’s commercial readiness ahead of Yutrepia’s approval in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the drug expected to be granted full approval in late Q2, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue